ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: L11

Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

Atul Deodhar1, Paula Sliwinska-Stanczyk2, Huji Xu3, Xenofon Baraliakos4, Lianne Gensler5, Dona Fleishaker6, Lisy Wang6, Joseph Wu6, Sujatha Menon6, Cunshan Wang6, Oluwaseyi Dina7, Lara Fallon8, Keith S Kanik6 and Désirée van der Heijde9, 1Oregon Health & Science University, Portland, OR, 2Reumatika Centrum Reumatologii, Warszawa, Poland, 3Shanghai Changzheng Hospital, Shanghai, China (People's Republic), 4Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany, 5University of California San Francisco, San Francisco, CA, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, New York, NY, 8Pfizer Inc, Montreal, QC, Canada, 9Leiden University Medical Center, Leiden, Netherlands

Meeting: ACR Convergence 2020

Date of first publication: October 23, 2020

Keywords: Ankylosing spondylitis (AS), clinical trial, Late-Breaking 2020, Randomized Trial

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2020

Session Title: Late-Breaking Abstracts (L06–L11)

Session Type: Late-Breaking Abstract Session

Session Time: 11:30AM-1:00PM

Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for the treatment of adult patients (pts) with AS.

Methods: This Phase 3, randomized, double-blind (DB), placebo (PBO)-controlled study (NCT03502616) enrolled pts aged ≥ 18 years with a diagnosis of active AS documented with centrally read radiographs, who met modified New York Criteria, and had an inadequate response or intolerance to ≥ 2 NSAIDs. In the 16-week DB phase, pts were randomized 1:1 to receive tofacitinib 5 mg BID or PBO. After Week (W)16, all pts received open-label tofacitinib until W48. We report the primary analysis of the study. Four separate families of efficacy endpoints were tested in hierarchical sequences to control for type I error: 1) ASAS20 response at W16 (primary endpoint), ASAS40 response at W16 (key secondary endpoint), change from baseline (∆) to W16 in ASDAS(CRP), hsCRP, ASQoL, SF‑36v2 PCS, BASMI–linear method, and FACIT-F total score; 2) ∆ to W16 in ASAS components: PtGA, total back pain, BASFI, and Inflammation (morning stiffness); 3) ASAS20 response over time; 4) ASAS40 response over time. Statistical tests were conducted at the 2-sided 5% significance level. Safety data up to W16 and up to W48 are presented (data cut-off Dec 19, 2019; database was not locked and study was ongoing).

Results: 269 pts were randomized and treated (tofacitinib, n=133; PBO, n=136); 77.0% were bDMARD-naïve (Table 1). Efficacy results are shown in Table 2. At W16, the % of ASAS20 responders was significantly greater with tofacitinib (56.4%) vs PBO (29.4%) (p < 0.0001). The % of ASAS40 responders at W16 was significantly greater with tofacitinib (40.6%) vs PBO (12.5%) (p < 0.0001), and significant improvements with tofacitinib vs PBO were seen for ∆ to W16 in ASDAS(CRP), hsCRP, ASQoL, SF‑36v2 PCS, BASMI–linear method, and FACIT-F total score. Improvements in ASAS components were significantly greater with tofacitinib vs PBO. Significant improvements with tofacitinib vs PBO were seen from W2 (first post-baseline visit) in ASAS20 response and W4 in ASAS40 response. Up to W16, adverse events (AEs) were reported in 72 pts (54.1%) receiving tofacitinib and 70 pts (51.5%) receiving PBO; serious and severe AEs were each reported in 2 pts (1.5%) receiving tofacitinib and no pts receiving PBO; 3 pts (2.3%) receiving tofacitinib and 1 pt (0.7%) receiving PBO discontinued study drug due to AEs. Safety trends were similar up to W48 (Table 3). With tofacitinib: there were no deaths, DVT, PE, ATE, GI perforation, ILD, MACE, malignancies, or opportunistic infections up to W48; adjudicated hepatic events were reported in 1 pt (0.8%) up to W16 and 2 pts (1.5%) up to W48; 1 pt (0.8%) had a serious infection (meningitis) up to W16; 3 pts (2.3%) had non-serious HZ up to W48. With PBO: there were no deaths or AEs of special interest up to W16; 1 pt (0.7%) in the PBO → tofacitinib group had non-serious HZ up to W48.

Conclusion: Pts with active AS had a rapid clinical response to tofacitinib. Efficacy was significantly greater with tofacitinib vs PBO for primary and secondary endpoints. AEs were more frequent with tofacitinib vs PBO; there were no new safety risks.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by Sarah Piggott, CMC Connect, and funded by Pfizer Inc.


Disclosure: A. Deodhar, Eli Lilly, 2, 5, GlaxoSmithKline, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, UCB, 2, 5, AbbVie, 2, 5, Amgen, 5, Boehringer Ingelheim, 5, Bristol-Myers Squibb, 5, Celgene, 5, Janssen, 5, Galapagos, 5, Gilead, 2, 5; P. Sliwinska-Stanczyk, None; H. Xu, None; X. Baraliakos, AbbVie, 5, Amgen, 5, Bristol-Myers Squibb, 5, Celgene, 5, Eli Lilly, 5, Gilead, 5, Janssen, 5, Novartis, 5, Pfizer Inc, 5, UCB, 5, MSD, 5; L. Gensler, Pfizer Inc, 2, AbbVie, 5, Eli Lilly, 5, Gilead, 5, GlaxoSmithKline, 5, Novartis, 2, 5, UCB, 2, 5; D. Fleishaker, Pfizer Inc, 1, 3; L. Wang, Pfizer Inc, 1, 3; J. Wu, Pfizer Inc, 1, 3; S. Menon, Pfizer Inc, 1, 3; C. Wang, Pfizer Inc, 1, 3; O. Dina, Pfizer Inc, 1, 3; L. Fallon, Pfizer Inc, 1, 3; K. Kanik, Pfizer Inc, 1, 3; D. van der Heijde, AbbVie, 5, Amgen, 5, Astellas, 5, AstraZeneca, 5, Bayer, 5, Bristol-Myers Squibb, 5, Boehringer Ingelheim, 5, Celgene, 5, Cyxone, 5, Daiichi, 5, Eli Lilly, 5, Galapagos, 5, Gilead, 5, GlaxoSmithKline, 5, Janssen, 5, Merck, 5, Novartis, 5, Pfizer Inc, 5, Regeneron, 5, Roche, 5, Sanofi, 5, Takeda, 5, UCB, 5, Imaging Rheumatology BV, 3.

To cite this abstract in AMA style:

Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler L, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O, Fallon L, Kanik K, van der Heijde D. Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/tofacitinib-for-the-treatment-of-adult-patients-with-ankylosing-spondylitis-primary-analysis-of-a-phase-3-randomized-double-blind-placebo-controlled-study/. Accessed February 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tofacitinib-for-the-treatment-of-adult-patients-with-ankylosing-spondylitis-primary-analysis-of-a-phase-3-randomized-double-blind-placebo-controlled-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.